



PATENT  
ST98032

#16

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): BRANELLEC ET AL. EXAMINER : MARVICH, M.  
SERIAL NO. : 09/787,995 ART UNIT : 1636  
FILED : JULY 9, 2001  
FOR : USE OF SPECIFIC HYBRID PROMOTERS FOR CONTROLLING  
TISSUE EXPRESSION

CERTIFICATE OF MAILING UNDER 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313 on 5/2/03.

William C. Cooper  
(Print Full Name)

[Signature] 5/2/03  
(Signature and Date)

TRANSMITTAL OF SUBSTITUTE SPECIFICATION  
(37 C.F.R. § 1.125)

COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231


Dear Sir:

1. Enclosed is a substitute specification for the originally filed specification in this application.
2. This substitute specification is submitted, in response to a requirement by the Examiner.
3. Also attached is a marked-up copy of the substitute specification showing the matter being added to and the matter being deleted from the specification. Material that has been

removed is within brackets and material that has been added is bolded.

4. Accompanying this transmittal is a statement as required by 37 C.F.R. § 1.125(b)(1), that the substitute specification transmitted herewith contains no new matter.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'William C. Coppola', written over a horizontal line.

William C. Coppola  
Registration No. 41,686

AVENTIS PHRAMACEUTICALS INC.  
Patent Department D303A  
Route 202-206  
P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Docket Number ST98032 US



PATENT  
ST98032

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): BRANELLEC ET AL. EXAMINER : MARVICH, M.  
SERIAL NO. : 09/787,995 ART UNIT : 1636  
FILED : JULY 9, 2001  
FOR : USE OF SPECIFIC HYBRID PROMOTERS FOR CONTROLLING  
TISSUE EXPRESSION

CERTIFICATE OF MAILING UNDER 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313 on 5/2/03.

William C. Coppola  
(Print Full Name)

[Signature] 5/2/03  
(Signature and Date)

STATEMENT THAT THE SUBSTITUTE SPECIFICATION CONTAINS NO NEW MATTER  
(37 C.F.R. § 1.125)

COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231

Dear Sir:

1. Identification of Person Making this Statement

William C. Coppola  
Aventis Pharmaceuticals Inc.  
Route 202-206, Bridgewater, NJ 08807-0800

The person making this statement is the attorney in this application, Registration Number 41,686.

2. Statement

I hereby state that the accompanying substitute specification contains no new matter over that contained in the above-identified application originally filed.

I further state that the changes made are the same as indicated in the interlined substituted specification also accompanying this statement. In the interlineated specification, material within brackets has been removed, and bolded material has been added.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'W. C. Coppola', written over a horizontal line.

William C. Coppola  
Registration No. 41,686

AVENTIS PHARMACEUTICALS INC.  
Patent Department D303A  
Route 202-206  
P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Docket Number ST98032 US